Compass Therapeutics, Inc. (CMPX)
| Market Cap | 139.35M -84.0% |
| Revenue (ttm) | n/a |
| Net Income | -86.36M |
| EPS | -0.46 |
| Shares Out | 180.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,550,026 |
| Open | 0.8300 |
| Previous Close | 0.8200 |
| Day's Range | 0.7510 - 0.8300 |
| 52-Week Range | 0.6714 - 6.8800 |
| Beta | 1.06 |
| Analysts | Buy |
| Price Target | 5.26 (+580.28%) |
| Earnings Date | Nov 9, 2026 |
About CMPX
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; C... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for CMPX stock is "Buy." The 12-month stock price target is $5.26, which is an increase of 580.28% from the latest price.
News
Compass Therapeutics Transcript: Stifel 2026 Healthcare Conference 2026
FDA re-engagement will focus on tovecimig’s crossover-adjusted survival data and a potential H1 next-year BLA, subject to FDA feedback. Pipeline updates are expected across CTX-10726, CTX-8371 and CTX-471, with cash runway well into 2028.
Compass Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
Four clinical-stage drugs are funded into 2028, with a focus on data-driven milestones. Tovecimig showed strong ORR and PFS activity in BTC, while FDA discussions on its regulatory path continue; pipeline updates are expected over the coming months.
Compass Therapeutics reports Q3 EPS (15c), consensus (13c)
“The third quarter was a period of sustained execution across our pipeline,” said Thomas Schuetz, Chief Executive Officer and Vice Chairman of the Board of Directors. “We continue to prepare…
Compass Therapeutics Reports 2026 Third Quarter Financial Results and Provides Corporate Update
Compass is advancing preparations for a BLA submission for tovecimig in patients with BTC and plans to further engage with the FDA. Data from the COMPANION-002 study of tovecimig, including newly disc...
Compass Therapeutics Quarterly report: Q3 2026
Compass Therapeutics has published its Q3 2026 quarterly earnings report on November 9, 2026.
Compass Therapeutics Earnings release: Q3 2026
Compass Therapeutics released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
Compass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual Meeting
CTX-10726, a PD-1 x VEGF-A bispecific antibody discovered and engineered at Compass, exhibits a unique mechanism of action that has not been previously reported in this class of drugs, characterized b...
Compass Therapeutics to Participate in Upcoming November Investor Events
BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to ...
Compass announces publication of Phase 2/3 COMPANION-002 study
Compass Therapeutics (CMPX) announced the publication of results from the positive Phase 2/3 COMPANION-002 study of tovecimig in combination with paclitaxel in patients with previously treated, advanc...
Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026
BOSTON, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to ...
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to ...
Compass Therapeutics price target lowered to $8 from $15 at Craig-Hallum
Craig-Hallum lowered the firm’s price target on Compass Therapeutics (CMPX) to $8 from $15 and keeps a Buy rating on the shares following FDA’s feedback that precludes tovecimig’s path forward…
Wedbush downgrades Compass Therapeutics as FDA throws wrench at tovecimig
As previously reported, Wedbush downgraded Compass Therapeutics (CMPX) to Neutral from Outperform with a price target of $1, down from $5. The firm notes the company announced that the FDA…
Compass Therapeutics price target lowered to $4 from $8 at Guggenheim
Guggenheim lowered the firm’s price target on Compass Therapeutics (CMPX) to $4 from $8 and keeps a Buy rating on the shares after the FDA recommended that Compass conduct a…
Compass Therapeutics price target lowered to $12 from $24 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Compass Therapeutics (CMPX) to $12 from $24 and keeps a Buy rating on the shares. The FDA wants a trial demonstrating a…
Compass Therapeutics price target lowered to $4 from $10 at Citizens
Citizens lowered the firm’s price target on Compass Therapeutics (CMPX) to $4 from $10 and keeps an Outperform rating on the shares. Compass is continuing discussions with the FDA after…
Compass Therapeutics downgraded to Neutral from Outperform at Wedbush
Wedbush downgraded Compass Therapeutics (CMPX) to Neutral from Outperform with a price target of $1, down from $5.
Compass Therapeutics downgraded to Market Perform from Outperform at LifeSci Capital
LifeSci Capital downgraded Compass Therapeutics (CMPX) to Market Perform from Outperform.
Compass Therapeutics says FDA requests new trial for tovecimig
Compass Therapeutics (CMPX) announced that the Food and Drug Administration recommended that Compass conduct a trial demonstrating a survival benefit before proceeding with a biologics license applica...
Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to...
Compass Therapeutics price target raised to $7 from $4 at Leerink
Leerink raised the firm’s price target on Compass Therapeutics (CMPX) to $7 from $4 and keeps an Outperform rating on the shares.
Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update
The Company expects feedback from the FDA this quarter regarding the COMPANION-002 Phase 2/3 data for tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), prior t...
Compass Therapeutics Earnings release: Q2 2026
Compass Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Compass Therapeutics Quarterly report: Q2 2026
Compass Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to ...